pembrolizumab based treatment for COVID-19: living meta-analysis of clinical studies

display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study

	metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)	metastatic/advanced RCC (mRCC) - 1st line (L1)

	metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)	metastatic/advanced RCC (mRCC) - 1st line (L1)
pembrolizumab based treatment
pembrolizumab alone	KEYNOTE-564
pembrolizumab plus axitinib		KEYNOTE-426
pembrolizumab plus lenvatinib		KEYNOTE-581/CLEAR ...

Study type: